Crossmark

A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy

Crossref DOI link: https://doi.org/10.1007/s11030-022-10406-8

Published Online: 2022-03-02

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shiri, Pezhman https://orcid.org/0000-0003-0071-6570
Ramezanpour, Sorour

Amani, Ali Mohammad

Dehaen, Wim https://orcid.org/0000-0002-9597-0629
License Information

Text and Data Mining valid from 2022-03-02

Version of Record valid from 2022-03-02
More Information

Article History

Received: 19 October 2021

Accepted: 7 February 2022

First Online: 2 March 2022

Declarations

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below